Why the study?
Recent evidence indicates differences in clinical characteristics and outcomes between de novo heart failure and acute decompensated chronic heart failure, but a better understanding of their distinct pathophysiology is needed to guide new treatment strategies.
Are there distinctive phenotypes and outcomes between de novo heart failure and acute decompensated chronic heart failure?
Are there distinctive phenotypes and outcomes between de novo heart failure and acute decompensated chronic heart failure?
De novo heart failure and acute decompensated chronic heart failure represent distinct phenotypes with different pathophysiology and outcomes, suggesting the need for tailored therapeutic strategies in future trials.
Supports distinct DNHF/ADCHF phenotypes; hypothesis-generating and should not yet change practice.
Heart failure is currently one of the leading causes of morbidity and mortality. Patients with heart failure often present with acute symptoms and may have a poor prognosis. Recent evidence shows differences in clinical characteristics and outcomes between de novo heart failure (DNHF) and acute decompensated chronic heart failure (ADCHF). Based on a better understanding of the distinct pathophysiology of these two conditions, new strategies may be considered to treat heart failure patients and improve outcomes. In this review, the authors elaborate distinctions regarding the clinical characteristics and outcomes of DNHF and ADCHF and their respective pathophysiology. Future clinical trials of therapies should address the potentially different phenotypes between DNHF and ADCHF if meaningful discoveries are to be made.
No takes yet. Share an insight, caveat, or question.
Raffaello et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: